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Compelling evidence indicates that alterations of intestinal homeostasis, such as “leaky” epithelial
barrier and changes in microbiota composition, can be associated with pathological adaptations
of brain functions (Carabotti et al., 2015). On the other hand, just as disrupted gut homeostasis
affects the brain, the brain can also exert a profound influence on the intestine as indicated by
the elicitation of inflammatory bowel disease (IBD) or IBD-like conditions following stress and
depression (for review see Di Giovangiulio et al., 2015). Recently, the recognition that microbiota
influences signaling pathways regulating the central nervous system (CNS) has led to the concept
of “microbiota–gut–brain axis” (Cryan and Dinan, 2012). Indeed, the routes of communication
between brain and intestinal microbes rely on the immune system activation, and on the capability
of microbiota to produce a number of neurochemicals (GABA, serotonin, dopamine) regulating
learning, memory, and mood (Dinan et al., 2015; Moloney et al., 2015).
With the evolving concept of psychoneuroimmunology the modalities by which the brain can
influence intestinal functions and vice versa are becoming more evident, although mechanistically
this bidirectional communication remains ill defined. For instance, patients with quiescent IBD
show an increased probability of relapse when encountering chronic stress, adverse life events and
depression (Mawdsley and Rampton, 2005). Similarly, the induction of an experimental depressive-
like state induced by olfactory bulbectomy in mice caused reactivation of colitis (Ghia et al., 2009),
suggesting that properly functioning central neuronal circuits are crucial for the maintenance of
gut homeostasis. On the other hand, changes of gut microbiota composition can directly affect
brain development in growing infants (Douglas-Escobar et al., 2013) and discrete perturbations
of intestinal microflora were shown to induce behavioral abnormalities in mice (Desbonnet et al.,
2015).
Chronic intestinal inflammation observed in IBD patients is also associated with extra-
intestinal symptoms including anxiety and depression-like behaviors (Graff et al., 2009) as well
as gastrointestinal morbidities induced by alterations of the autonomic nervous system (ANS;
Lindgren et al., 1993). Motility, secretion and vasoregulation are controlled by sympathetic and
parasympathetic extrinsic branches, consisting of noradrenergic nerves dynamically interacting
with immune cells and enteric neurons (located in the mucosa and the submucosa), and the vagus
nerve broadly innervating the intestinal wall up to the myenteric plexus. An increase in brain
cholinergic activity attenuates experimental colitis by the initiation of vagal anti-inflammatory
pathways in the periphery (Ghia et al., 2006), whereas via their efferents to gut-associated lymphoid
tissues including Payer’s patches and mesenteric lymph nodes, sympathetic fibers directly influence
plasma cell, T cell and dendritic cell responses and suppress cytokine secretion and macrophage
phagocytosis (Di Giovangiulio et al., 2015).
Despite anatomical, preclinical and clinical evidence, the identity of neurons and the circuitry
governing the gut-brain bidirectional communication are still largely unknown. Methodological
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difficulties associated with unraveling discrete circuits regulating
the gut-brain axis have slowed down the achievement of crucial
and clinically meaningful information.
Recently new technologies became available that allow
unprecedented opportunities for manipulating neurons and
circuits. These new tools accelerated neuroscience research over
the last 10 years to a vertiginous speed; a step change that has
changed both experimental approaches and research questions.
Just like any other circuits, neuronal circuits can be now turned
on and off, providing the availability of one or more switchers
positioned at defined circuit’s nodes. For neurons, switchers are
(mostly) receptors that have been engineered to be remotely
operated. Genetics provides then a means to express such
switchers within the circuits. Switchers activated by drugs are
collectively defined as chemogenetics (for review see Sternson
and Roth, 2014), while switchers activated via light sources are
named optogenetics (for review see Tye and Deisseroth, 2012;
Figures 1A,B).
CHEMOGENETICS
The chemogenetic platform known as DREADDs (designer
receptors exclusively activated by designer drugs) has already
shown to be suitable for manipulating neuronal activity in
cell types as diverse as glia, pancreatic β-cells, hepatocytes,
FIGURE 1 | The proposed tools to study the gut-brain axis include the increasingly popular chemogenetic platform known as DREADD and
optogenetics. In panel (A) the principles of the chemogenetic technology are schematized: these include the delivery of a DREADD encoding vector, the expression
of the designer receptor in the cell population of interest, and the modulation of this receptor by a designer drug. In panel (B) the principles of the optogenetic
technology and the mechanisms by which commonly used opsins modulate cell activity are schematized and simplified. In panel (C) two examples of cell-specific
delivery strategies are reported. Left, in Cre-inducible viral vector the gene of interest is initially positioned in a non-coding orientation; following Cre-mediated
recombination the gene of interest is flipped in a coding orientation allowing cell-specific expression. Right, an example of cell-specific targeting by using transgenic
mouse lines. When a Cre reporter transgenic mouse line is crossed with a Cre-inducible opsin or DREADD knock-in line cell-specific expression can be achieved.
fibroblasts, and induced pluripotent stem cells. This technology
allows the expression of designer receptors whose affinity for
endogenous ligands is lost, while affinity for an otherwise inert
designer ligand is gained (Figure 1A). For example, DREADDs
can be designer muscarinic receptor variants activated by the
biologically inert designer drug clozapine-N-oxide (CNO).When
CNO binds to DREADD it modulates cellular signaling via
G protein-coupled receptor cascades. In vivo according to the
nature of designer receptors employed (Gq-, Gs-, or Gi-coupled),
a systemic administration of a designer drug therefore directly
modulates the activity of transduced cells (Alexander et al., 2009).
DREADDs can be delivered in rodents via viral systems,
including adeno-associated viral vectors that express DREADDs
only following Cre-mediated recombination, thus facilitating
the targeting of genetically defined cell populations (Figure 1C;
Krashes et al., 2011).
However, viral systems require localized injections within
discrete brain areas or, where possible, localized administrations
into the organ of interest—a possible limitation in the context
of gastrointestinal manipulations. While it is possible to
envision intracolonic inoculation of viral particles, targeting
the upper intestinal tract could prove difficult. Nevertheless,
knock-in mouse models bearing different DREADD alleles
are also available, enabling the expression of DREADD
variants within the tissue of interest when crossed with a
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specific Cre-reporter mouse line (Figure 1C; Alexander et al.,
2009).
Chemogenetic tools are not limited to muscarinic-derived
DREADD. Designer receptors based on ion channels (Magnus
et al., 2011) or an inhibitory designer receptor derived from
the κ opioid receptor have also been developed (Vardy
et al., 2015); this variety of chemogenetic tools has also the
advantage to allow multiplexed approaches. For instance,
co-expression of designer receptors activated by different
designer drugs allows bidirectional modulation of cell
activity within the same experimental subject (Vardy et al.,
2015).
The chemogenetic toolbox is continuously growing and today
chemogenetics represents undoubtedly an accessible and easy-to-
implement technology for on demandmodulation of cell activity.
However, the main limitation of this technology is the lack of
temporal control following the administration of a designer drug
and the activation of DREADDs, with both onset and duration of
the elicited “physiological” phenomena being mainly dictated by
the pharmacokinetic features of the designer drug used.
OPTOGENETICS
Cell activity can also be modulated via optogenetic technologies
that use light sources to control living tissues, genetically
engineered to express light-sensitive proteins (opsins). The most
common and best characterized opsins used in optogenetics
are: (i) channelrhodopsin 2 (ChR2), able to elicit action
potentials time locked to blue light pulses; (ii) halorhodopsin,
a yellow light-gated ion pump that moves chloride ions into
the cell; and (iii) archaerhodopsin, a green light-driven proton
pump that moves protons out of the cell. Halorhodopsin
and archaerhodopsin variants have the net effect of silencing
active neurons by enabling hyperpolarization of membranes
and reducing the likelihood of action potential generation
(Figure 1B). Although technically more challenging compared
to chemogenetics, this approach offers at least three main
advantages: (i) the temporal control over the modulation of cell
activity; (ii) the definition of firing patterns with millisecond
resolution (owing to the possibility of rapidly modulating the
light pulse); and (iii) the manipulation of specific projection
sites within the CNS or, notably, in the proximity of innervated
organs (due to the capacity of opsins to diffuse along axons and
localize at synaptic terminals). The latter is one of the most
attractive features of this technique. Indeed, viral transduction
strategies enable anterograde-like targeting capabilities, where
opsins are expressed in local cell bodies and trafficked to
downstream terminals; here, opsin-expressing projections can
then be illuminated to control cells by virtue of their efferent
connectivity. A proof of concept regarding how optogenetics
could be useful in studying the neuronal control of peripheral
organ function was recently published. Zeng et al. showed that
local optogenetic stimulation of sympathetic inputs at neuro-
adipose junctions promotes a local lipolytic response with
consequent depletion of the mouse white adipose mass (Zeng
et al., 2015).
Although for routine application of optogenetic it is still
necessary tethering the experimental subject to lasers or LED
light sources, ongoing lines of research also focus on the
implementation of portable and implantable micro devices
that can be carried by animals during enacted behavior (Kim
et al., 2013; Montgomery et al., 2015; Park et al., 2015). While
implementation and easy-access to such devices will be a major
advance for the neuroscience field as a whole (for review see
Kale et al., 2015), implantable and wireless devices will be crucial
for a full incorporation of optogenetics into the gastrointestinal
research.
OTHER APPROACHES
While chemo- and opto-genetic approaches enable on
demand control of neuronal activity, these technologies
(like pharmacological agents) can modulate cell activity in a
“non-physiological” manner—this caveat is particularly true
when activation strategies are used. Despite the availability of
reversible inhibitory chemo- and opto-genetic tools, long-term
and cell-specific loss of function approaches are often crucial to
test the physiological meaning of a given system (i.e., appearance
of phenotype). In this respect, a number of approaches allow
permanent inactivation of cell functions. Specific subset of
neurons can be genetically manipulated to express the diphtheria
toxin (DT) receptor. DT-expressing neurons are ablated by
systemically administering DT (Saito et al., 2001). With this
approach the experimenter maintains control over the onset of
the ablation, an advantage when the role of a given neuronal
population has to be interrogated at a specific developmental
or disease stage. Similarly, a viral system to promote death of
discrete cell populations by expressing a Cre-inducible form of
caspase-3 was recently developed (Morgan et al., 2014). Likewise,
the expression of an allele encoding the tetanus toxin light chain
in genetically defined neuronal populations has proven effective
in blocking vesicle release in different experimental conditions
(Kim et al., 2009; Xu and Südhof, 2013). Tetanus toxin-based
approaches would bypass the need of inducing cell death, thus
possibly minimizing the potentially detrimental effect that
neuronal death may cause on surrounding non-targeted cells,
although confirming that the loss of secretory activity can be
difficult.
Besides efferent and afferent activity of the ANS, neuronal
regulation of gut homeostasis also originates locally within the
intestine, through its own independent nervous system, namely
enteric nervous system (ENS): an intricate network of over 100
million neurons grouped in the Auerbach and the Meissner
plexi. Enteric fibers projecting to Peyer’s Patches and in close
vicinity of immune cells control inflammation by means of
neurotransmitters, neuropeptides or other signaling molecules
(Di Giovangiulio et al., 2015). Thus, tools developed for the
manipulation of central circuits will be also useful to interrogate
discrete local cell populations within the ENS. For instance,
intracolonic inoculation of viral vectors expressing chemogenetic
or optogenetic tools could be a strategy to target genetically
defined enteric neurons by means of Cre reporter transgenic
mouse lines or by using specific neuronal subtype promoters
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(Figure 1C). Likewise, transgenic mouse lines harnessed to
express chemogenetic and optogenetic receptors will provide an
invaluable source of intestinal tissue amenable to evaluate ex vivo
either secretory or contractile activity.
CONCLUSIONS
Owing to their relatively recent development, technologies for
neuronal circuit manipulation have been used to interrogate
brain networks underpinning behavior and the brain’s processing
of sensory information. However, the first evidence of their
usefulness within the gastrointestinal tract has been recently
reported. For instance, a chemogenetic mouse line expressing
DREADDs under transcriptional control of the glial fibrillary
acidic protein promoter (GFAP; a marker for astrocytes) was
used to study intestinal motility by evoking glial Ca2+ responses
(McClain et al., 2015).
The selectivity and wide range of manipulations that are
now possible with these technologies offer an unprecedented
and fascinating opportunity to expand our understanding
of the gut-brain axis, the behavioral effects associated with
intestinal homeostasis alterations and the gut responses
following discrete manipulation of defined neuronal
networks.
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